Holen Sie sich die Stockscreener-App
0.2418
1.46%
-0.0041
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - Investing.com
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board - Stock Titan
Plus Therapeutics appoints Ron Andrews to board of directors By Investing.com - Investing.com India
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors - Yahoo! Finance Canada
Aug Action: Will Plus Therapeutics Inc benefit from rising consumer demandPortfolio Return Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
If You Invested $1,000 in Grace Therapeutics, Inc (GRCE) - Stock Titan
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PSTV Analyst Rating: D. Boral Capital Maintains Buy Rating | PST - GuruFocus
Plus Therapeutics Presents Analysis Showing CNSide May Reduce Leptomeningeal Metastases Costs by 40% - National Today
Plus Therapeutics (PSTV) Study Highlights Cost Benefits of Early LM Detection - GuruFocus
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs - Intellectia AI
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting - The Globe and Mail
Plus: Q4 Earnings Snapshot - theheraldreview.com
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline - GuruFocus
Plus Therapeutics (PSTV) Surpasses Q4 Revenue Expectations - GuruFocus
Plus Therapeutics Reports 2025 Results, Advances CNSide Commercial Rollout and REYOBIQ Clinical Program with 2026 Milestones - Minichart
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Shareholder Director Nomination Procedures and Company Information - Minichart
Plus Therapeutics, Inc. 2025 Annual Report: Precision Radiopharmaceuticals and CNS Cancer Innovations - Minichart
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance
Plus: Q4 Financial Overview - Bitget
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout - Bitget
Plus Therapeutics 2025 net loss widens - TradingView
[8-K] PLUS THERAPEUTICS, INC. Reports Material Event | PSTV SEC FilingForm 8-K - Stock Titan
Plus Therapeutics 10-K: $5.21M Grant Revenue, Net Loss $0.29 EPS - TradingView
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Plus Therapeutics (NASDAQ: PSTV) updates CNS oncology pipeline and CNSide - Stock Titan
Plus Therapeutics (PSTV) widens 2025 loss but strengthens cash and CNS programs - Stock Titan
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire
Plus Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
PSTV Earnings History & Surprises | EPS & Revenue Results | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Can Plus Therapeutics Inc. stock deliver strong Q4 earningsEarnings Miss & Verified Short-Term Trading Plans - Naître et grandir
[RW] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Stocktwits
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics announces new Category III CPT code - marketscreener.com
Plus Therapeutics Receives AMA Approval for New CPT Code for REYOBIQ in Treatment of CNS Cancers - Quiver Quantitative
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewswire
PSTV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Value Recap: Is Plus Therapeutics Inc stock undervalued right nowWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Plus Therapeutics Inc stock undervalued right nowMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Is Plus Therapeutics Inc. in accumulation or distribution phase2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):